hepatocellular carcinoma

Overview

Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer and represents a major global health burden, particularly in regions with high prevalence of hepatitis B virus (HBV) and hepatitis C virus (HCV) infection. The disease develops predominantly in the context of chronic liver disease, including cirrhosis, and is increasingly associated with metabolic dysfunction–associated steatotic liver disease. HCC typically arises from malignant transformation of hepatocytes and is characterized by rapid progression, high mortality rates, and limited therapeutic options in advanced stages. Understanding the molecular pathogenesis of HCC and identifying new therapeutic targets and prognostic biomarkers remains critical for improving patient outcomes.

Recent Publications Summary

Recent research has identified multiple therapeutic strategies targeting distinct molecular pathways in HCC. A novel matrine derivative, compound B10, demonstrated potent anticancer activity against hepatocellular carcinoma cell lines, achieving IC₅₀ values of 4.13-5.79 µM with greater than 1000-fold improvement in efficacy compared to the parent compound matrine, while exhibiting minimal toxicity toward normal hepatocytes 41533014Jan. Complementary approaches targeting alternative pathways include β,β-dimethylacrylshikonin (DMAS), a phytochemical that suppresses HCC progression through induction of mitochondrial stress and impairment of TGM2-associated mitophagy, suggesting that modulation of apoptotic process and cellular stress responses represents a viable therapeutic strategy 42176510May.

Mechanistic investigations have unveiled PCLAF as a prognostic and druggable target for HBV-associated hepatocellular carcinoma, identified through integrated multi-omics analyses that characterized its clinical significance, biological functions, and potential for therapeutic intervention 42486346Jul. Immunotherapeutic approaches are being refined through characterization of neoantigen-encoding tumor-specific transcripts (neoTSTs) in HCC, which may serve as a shared target reservoir for T-lymphocyte-based immunotherapy and represent generation of novel checkpoint inhibitor candidates 42481156Jul.

Clinical understanding of HCC pathogenesis has been expanded by case documentation of malignant transformation from benign focal nodular hyperplasia to hepatocellular carcinoma, illustrating potential mechanisms of neoplastic progression over prolonged periods 42392677Jul. Risk stratification capabilities have been substantially advanced through development of PRE-Screen-HCC, an interpretable machine learning framework leveraging multimodal clinical data that significantly outperforms conventional risk scores and demonstrates robust performance across diverse ethnic subgroups, with potential application in population-based screening 42381462Jul.

Novel nanotherapeutic platforms are being developed to enhance treatment efficacy, including FeCo dual-atom site nanozyme hybrid microneedle patches integrating multienzyme catalysis with near-infrared photothermal therapy, achieving complete tumor eradication in vivo models through synergistic antihepatoma effects 42333601Jun. Targeting cell-cell communication pathways, artificial gap junctional channels have been engineered to inhibit hepatocellular carcinoma cell proliferation, providing an alternative mechanism for growth suppression 42251683Jun. Collectively, these investigations identify diverse molecular targets—including FGFR3/PI3K/AKT signaling, mitochondrial dynamics, immune checkpoint pathways, and reactive oxygen species generation—as avenues for developing next-generation therapeutic interventions that complement existing treatments such as sorafenib, lenvatinib, atezolizumab, and bevacizumab in the management of advanced HCC.

What Changes, What Holds

1. New compounds broaden the therapeutic map without displacing the current disease model
REINFORCES Matrine-derivative and phytochemical studies add more candidate anti-HCC agents and point to mitochondrial stress, mitophagy disruption, and cell-death pathways as druggable vulnerabilities, but they do not alter the baseline view of HCC as a hepatocyte-derived malignancy arising in chronic liver disease. The main implication is practical: these are preclinical leads that may expand the treatment pipeline, not evidence that the disease biology itself has been redefined. 41533014Jan42176510May

2. HBV-associated HCC may have a new prognostic target, and immunotherapy may gain shared neoantigen targets
NEW DIRECTION PCLAF adds a potentially actionable marker for the HBV-linked subset of HCC, which the Overview does not previously single out at the molecular target level, while neoTSTs suggest a route to broader T-cell-based immunotherapy design. These findings extend the baseline emphasis on unmet therapeutic need, but they remain early and do not yet establish clinical utility or replace existing biomarkers and checkpoint-based approaches. 42486346Jul42481156Jul

3. Risk prediction and rare precursor-to-cancer progression are becoming more clinically legible
METHOD PRE-Screen-HCC changes how HCC risk may be identified by using interpretable multimodal prediction rather than conventional scores, and the focal nodular hyperplasia case reminds readers that benign-appearing lesions can, rarely, precede carcinoma over long intervals. The baseline already recognizes chronic liver disease as the usual setting; what changes here is the granularity of surveillance and the reminder that long-term diagnostic uncertainty can matter. 42381462Jul42392677Jul

4. Physical and communication-based delivery strategies add experimental routes to tumor control
REINFORCES Nanozyme microneedle patches and artificial gap junction channels expand the menu of experimental anti-HCC platforms, but they sit squarely within the established search for better treatment of advanced disease rather than overturning it. Their significance is that they combine local delivery, catalytic stress, and intercellular signaling interference in ways that may complement sorafenib, lenvatinib, atezolizumab, and bevacizumab, not replace the baseline therapeutic framework. 42333601Jun42251683Jun

Overview update candidates: PCLAF as a prognostic/druggable target in HBV-associated HCC; neoTSTs as shared immunotherapy targets; PRE-Screen-HCC as a clinically useful risk-stratification framework.